Salute e Benessere

Strategic Collaboration Formed Between Leo Cancer Care and Sumitomo Heavy…

Upright proton therapy represents the biggest step forward in making proton therapy mainstream in a generation. Not only will it reduce the barriers of size and cost that have limited adoption for decades, growing research suggests remaining upright for treatment, our natural position, could support more consistent anatomical positioning while offering patients a more comfortable and connected patient experience. Upright proton therapy represents the biggest step forward in making proton...
PR Newswire
26/09/2025

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARES Ghent, Belgium, 26 September 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today a capital increase in the framework of (i) a contribution in kind of certain convertible receivables (for an aggregate amount of EUR 214,000.00) due under the...
Nasdaq GlobeNewswire
26/09/2025

Smart Sleep Tracker Market is expected to generate a revenue of USD 68.31…

The Smart Sleep Tracker Market is gaining momentum as consumers prioritize sleep health and wellness. With advancements in wearable technology, mobile health apps, and AI integration, the market is evolving into a key segment of the digital health industry, offering strong growth potential globally. The Smart Sleep Tracker Market is gaining momentum as consumers prioritize sleep health and wellness. With advancements in wearable technology, mobile health apps, and AI integration, the market…
PR Newswire
26/09/2025

Fluoropolymer Tubing Market worth $813.5 million by 2030 - Exclusive Report by…

240 - Tables46 - Figures280 - Pages 240 - Tables 46 - Figures 280 - Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=165466482 The market for fluoropolymer tubing is growing due to its unique combination of chemical resistance, durability, and performance in demanding environments. Industries such as pharmaceuticals, semiconductors, automotive, and chemicals increasingly rely on fluoropolymers because they can withstand extreme temperatures,...
PR Newswire
26/09/2025

Philips unveils latest CT and MR innovations in radiation therapy, advancing…

New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term valuePhilips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology Amsterdam, the Netherlands –At the American Society for Radiation Oncology ( ASTRO ) 2025 Annual Meeting,Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health...
Nasdaq GlobeNewswire
26/09/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 26 September 2025 at 16.30 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 25...
Nasdaq GlobeNewswire
26/09/2025

Medical Drones Market Set for 22.19% CAGR from 2025 to 2030, Driven by Expanding…

Expanding Role of Medical Drones Expanding Role of Medical Drones Medical drones are rapidly emerging as a critical component of modern healthcare delivery. Their adoption is accelerated by government pilot programs, public-private collaborations, and technological advancements in autonomous flight and navigation. Emerging Trends Growing Use in Emergencies and Disasters:During natural calamities or in conflict zones, drones provide uninterrupted medical supply access where...
PR Newswire
26/09/2025

GUINEA-BISSAU AND ANTARES VISION GROUP EXPAND COLLABORATION TO ADVANCE…

Building on the landmark agreement signed in February 2025 and the Minister's official visit to AV Group's headquarters in May, the collaboration is expanding into new strategic areas. These include establishing local pharmaceutical manufacturing capacities supported by Serialisation-as-a-Service solutions and extending traceability requirements into the medical devices sector, further reinforcing Guinea-Bissau's role as a regional leader in digital health. Building on the landmark agreement...
PR Newswire
26/09/2025

Aker Carbon Capture ASA: Notice of Extraordinary General Meeting

Although no pre-registration is needed for attending online, shareholders that are eligible for attending and voting at the extraordinary general meeting, are encouraged to register their attendance no later than 15 October 2025 at 16:00 (CEST). Shareholders owning shares through a custodian in the VPS are required to register via their custodian by this deadline. Attendees must be logged in before the meeting starts to be able to vote. Deadline for registration of advance votes and proxies is…
PR Newswire
26/09/2025

Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis

Skin barrier research is a fast-growing field in dermatology, including the development of new diagnostic methods, therapeutics, aesthetic products, and scientific investigations of diseases related to the skin barrier. Disruption of skin barrier function plays a key role in the development and severity of several skin diseases such as atopic dermatitis. Skin barrier research is a fast-growing field in dermatology, including the development of new diagnostic methods, therapeutics, aesthetic...
PR Newswire
26/09/2025

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice…

The 2025 update defines remission of proteinuria (<0.5 g/day, or ideally at <0.3 g/day) and slowing eGFR decline as key treatment goals. To achieve these goals, the guidelines recommend a treatment approach with therapies simultaneously targeting IgAN-induced nephron loss and IgA-formation. The 2025 update defines remission of proteinuria (<0.5 g/day, or ideally at <0.3 g/day) and slowing eGFR decline as key treatment goals. To achieve these goals, the guidelines recommend a…
PR Newswire
26/09/2025

Novartis to showcase transformative data in advanced prostate and early breast…

Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of Pluvicto TMplus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-year analysis of Kisqali ®to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population New data for Pluvicto in prostate cancer and Kisqali in breast cancer strengthen the profiles of both medicines, with promise for new SoC in...
Nasdaq GlobeNewswire
26/09/2025

Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results…

Geneva, Switzerland, September 26, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will...
Nasdaq GlobeNewswire
26/09/2025

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce…

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnemo: OSE),Inserm Transfert(on behalf of Inserm, a French public organization dedicated to human health), andNantes Universitytoday announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative...
Nasdaq GlobeNewswire
26/09/2025

uniQure Announces Pricing of Upsized $300 Million Public Offering

Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen are acting as bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying...
Nasdaq GlobeNewswire
26/09/2025

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; September 26, 2025 –Genmab A/S(Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market...
Nasdaq GlobeNewswire
26/09/2025

TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche…

Key Takeaways from the TL1A Binder Market Report Key Takeaways from the TL1A Binder Market Report Discover which indication is expected to grab the major TL1A binder market share @TL1A Binder Market Report Key Factors Driving the TL1A Binder Market Rising Prevalence of Inflammatory Bowel Disease (IBD) The global incidence of IBD, encompassing Crohn's disease and ulcerative colitis, is on the rise. The total diagnosed prevalent cases of Crohn's disease inthe United...
PR Newswire
25/09/2025

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment…

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegalyApproval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in rapid, durable, and consistent biochemical control and reduced symptom burdenLaunch of lead product PALSONIFY marks a pivotal milestone for Crinetics as the premier endocrine-focused global pharmaceutical companyInvestor call to...
Nasdaq GlobeNewswire
25/09/2025

EssilorLuxottica: Essilor Stellest is the first and only FDA market authorized…

Essilor Stellest is the first and only FDA marketauthorized spectacle lens in the United States EssilorLuxottica’s lens is clinically proven to slow myopia progression in children 1 ,2 Paris, France (25 September 2025)– EssilorLuxottica today announced the U.S. Food and Drug Administration (FDA) has granted market authorization for its Essilor Stellest lens using the De Novo pathway. This follows the product’s earlier recognition with the FDA granting designation as a...
Nasdaq GlobeNewswire
25/09/2025

Teva Releases Q3 2025 Aide Memoire

Q3 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered...
Nasdaq GlobeNewswire
25/09/2025

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at…

In order to participate, please register in advancehere to obtain a local or toll-free phone number and your personal pin.A live webcast of the call will be available on Teva's website at:https://ir.tevapharm.com/Events-and-Presentations.Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled...
Nasdaq GlobeNewswire
25/09/2025

Axon Therapies Raises $32M in Oversubscribed Series A to Transform Heart Failure…

The financing will accelerate Axon's next phase of clinical development, including two double-blinded randomized feasibility studies in heart failure – a condition that affects millions of people worldwide with limited treatment options. The first is a confirmatory study for its novel splanchnic ablation therapy in patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The second is a multiple-center study of splanchnic ablation in Failure with Reduced Ejection Fraction (HFrEF)…
PR Newswire
25/09/2025

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

OSE Immunotherapeutics Reports its Cash Positionas of June 30, 2025Nantes, France, September 25, 2025, 6 p.m. CET-OSE Immunotherapeutics SA( ISIN: FR0012127173; Mnemo: OSE)reports its cash position as of June 30, 2025. Due to the Company’s Annual General Meeting being rescheduled to September 30, 2025, and to allow shareholders to first approve 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025. Update on...
Nasdaq GlobeNewswire
25/09/2025

THERANEXUS ANNOUNCES FIRST HALF 2025 FINANCIAL RESULTS

THERANEXUS ANNOUNCES FIRST HALF 2025 FINANCIAL RESULTS Lyon, France – 25 September 2025 – 6pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its first half results as of 30 June 2025. Mathieu Charvériat, Chairman and CEO of Theranexus, comments: “We have maintained the focus…
Actusnews Wire
25/09/2025
Altri  Comunicati